25th July 2018, SomnoMed Limited (ASX:SOM) announced today that its Q4 revenues were $17.4 million (unaudited), representing growth of 22% over the same quarter last year, and bringing the total for the year to $64.2 million (unaudited), a growth of 30% over prior year.
Group revenue growth in the three key regions for Q4 was 12% in North America (36% full year), 33% for Europe (29% full year), 10% for APAC (5% full year). Overall, the SomnoMed Core business (ex RSS), showed Q4 growth of 14% (11% full year), with revenues of $14.8 million, while Renew Sleep Solutions (“RSS”) showed 99% growth, with revenues of $2.6 million. RSS full year revenues were $11.2 million, up from $1.6 million in 2017.
For further information please download PDF attached:
Download this document
